Diabetes mellitus Cardiovascular disease
Conditions
Interventions
All included subjects will receive three dosingregimens of aspirin treatment
starting at 30 mg per day for ten days,
followed by 100 mg per day for ten days
and finally 300 mg per day for ten days
Sponsors
Prof. dr. J.B.L. Hoekstra
Dept. of Internal Medicine
Academic Medical Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age > 18 years 2. Diagnosis of type 2 diabetes
Exclusion criteria
Exclusion criteria: 1. Current acetylsalicylic acid therapy 2. Use of any medication interfering with platelet function, e.g. diclofenac, naproxen or clopidogrel in the two weeks prior to the study. 3. Abnormal platelet count, < 100.000/ mm3 4. Allergy or hypersensitivity to prostaglandinsynthetase inhibitors 5. Hemorrhagic stroke in medical history 6. Gastric complaints or gastritis/ulcus pepticum, history of gastric bleeding 7. Known coagulation disorders 8. Severe liver or kidneyfailure 9. Substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the prevalence of laboratory measured aspirin resistance stratified by level of glycaemic control | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is the ability of increased dosing to overcome laboratory measured aspirin resistance in type 2 diabetes mellitus. | — |
Contacts
Public ContactB.A. Lemkes
Dept. of Internal Medicine, Academic Medical Centre
Outcome results
None listed